Loading company
Castle Biosciences Inc.
CSTL · Nasdaq · ·
Next earnings: November 2, 2026
$34.87-2.9%Sep 29 close
- 1M
- +4.1%
- 6M
- +48.1%
- 1Y
- +53.1%
- 5Y
- -51.0%
CSTL · Nasdaq · ·
Next earnings: November 2, 2026
$34.87-2.9%Sep 29 close
Castle Biosciences Inc. is scheduled to report next on November 2, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $103.5M | $86.2M | +20.14% |
| Profit | -$2.1M | $4.5M | -145.54% |
| Profit per share | -$0.07 | $0.15 | -146.67% |
| Free Cash Flow | $6.6M | $11.6M | -43.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes. We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram . DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Castle Biosciences Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Castle Biosciences Inc. has no earnings call transcript available.